Research & Clinical Trials
More people are surviving end-stage organ disease than ever before. Over the last decade, many people with lung disease have witnessed the success of research studies that have helped improve and increase treatment options.
As an experienced transplant center in an academic setting, Penn Transplant Institute is committed to finding new and better treatments for transplant patients.
Lung transplant research at Penn Medicine focuses on novel therapeutics and immunosuppression strategies for advanced lung disease with programs dedicated to interstitial lung disease, adult cystic fibrosis, pulmonary vascular disease and management of COPD. A minimally invasive surgical approach to lung transplant is standard practice at Penn.
Current Clinical Trials
- Dietary Antioxidant Therapy in Patients Awaiting Lung Transplantation
-
- Investigator: James Lee, MD
- Clinical Risk Factors of Primary Graft Failure, a Multicenter Study
-
- Investigator: Jason D. Christie, MD
- Genetics of Primary Graft Failure, a Multicenter Study
-
- Investigator: Jason D. Christie, MD
- Clinical Trials in Organ Transplantation
-
- Investigator: Jason D. Christie, MD
- The HLA Antibodies after Lung Transplantation (HALT) Study
-
- Investigator: Vivek N. Ahya, MD
Advanced Lung Disease Research Studies
Bronchiectasis
- A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1), Gilead
-
- Investigator: Gregory Tino, MD
- A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions (NON-TREATMENT)
-
- Investigator: Gregory Tino, MD
IPF
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, InterMune (TREATMENT)
-
- Investigator: Gregory Tino, MD
- NAC vs. Placebo, PANTHER – IPFNet trial (TREATMENT)
-
- Investigator: Milton Rossman, MD
- A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis (TREATMENT)
-
- Investigator: Milton Rossman, MD
- PA-IPF Registry(NON-TREATMENT)
-
- Investigator: Milton Rossman, MD
For more information about clinical trials at the Penn Transplant Institute, see Research & Clinical Trials.